AbbVie Future Growth

Future criteria checks 4/6

AbbVie is forecast to grow earnings and revenue by 31% and 7.1% per annum respectively. EPS is expected to grow by 31.2% per annum. Return on equity is forecast to be 303.2% in 3 years.

Key information

31.0%

Earnings growth rate

31.16%

EPS growth rate

Biotechs earnings growth	25.5%
Revenue growth rate	7.1%
Future return on equity	303.17%
Analyst coverage	Good
Last updated	23 Oct 2025

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NYSE:ABBV - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	71,110	19,845	28,172	30,070	22
12/31/2026	66,201	16,434	25,703	27,350	24
12/31/2025	60,663	8,982	18,138	19,813	26
6/30/2025	58,328	3,723	18,239	19,283	N/A
3/31/2025	57,367	4,155	15,385	16,401	N/A
12/31/2024	56,334	4,238	17,832	18,806	N/A
9/30/2024	55,533	5,081	15,623	16,511	N/A
6/30/2024	55,000	5,298	17,780	18,638	N/A
3/31/2024	54,403	5,951	21,891	22,686	N/A
12/31/2023	54,318	4,820	22,062	22,839	N/A
9/30/2023	55,138	6,471	24,729	25,514	N/A
6/30/2023	56,023	8,635	24,799	25,542	N/A
3/31/2023	56,741	7,535	23,520	24,228	N/A
12/31/2022	58,054	11,782	24,248	24,943	N/A
9/30/2022	57,819	13,343	21,921	22,590	N/A
6/30/2022	57,349	12,569	22,214	22,923	N/A
3/31/2022	56,725	12,407	22,047	22,808	N/A
12/31/2021	56,197	11,468	21,990	22,777	N/A
9/30/2021	55,169	7,465	21,677	22,556	N/A
6/30/2021	53,729	6,599	19,572	20,451	N/A
3/31/2021	50,195	5,092	17,789	18,650	N/A
12/31/2020	45,804	4,556	16,790	17,588	N/A
9/30/2020	40,650	7,324	15,327	16,009	N/A
6/30/2020	36,227	6,906	14,115	14,734	N/A
3/31/2020	34,057	8,395	13,552	14,122	N/A
12/31/2019	33,266	7,842	12,772	13,324	N/A
9/30/2019	32,867	3,232	12,929	13,441	N/A
6/30/2019	32,624	4,093	12,770	13,410	N/A
3/31/2019	32,647	5,333	N/A	13,799	N/A
12/31/2018	32,753	5,657	N/A	13,427	N/A
9/30/2018	32,187	7,531	N/A	12,619	N/A
6/30/2018	30,946	6,419	N/A	11,366	N/A
3/31/2018	29,612	6,352	N/A	10,503	N/A
12/31/2017	28,216	5,283	N/A	9,960	N/A
9/30/2017	27,273	6,615	N/A	8,917	N/A
6/30/2017	26,710	6,582	N/A	7,100	N/A
3/31/2017	26,218	6,278	N/A	7,015	N/A
12/31/2016	25,638	5,923	N/A	7,041	N/A
9/30/2016	25,242	6,048	N/A	7,463	N/A
6/30/2016	24,754	5,690	N/A	8,164	N/A
3/31/2016	23,777	5,448	N/A	8,078	N/A
12/31/2015	22,859	5,118	N/A	7,535	N/A
9/30/2015	21,911	2,790	N/A	4,994	N/A
6/30/2015	20,986	2,064	N/A	4,625	N/A
3/31/2015	20,437	1,802	N/A	4,510	N/A
12/31/2014	19,960	1,765	N/A	3,549	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABBV's forecast earnings growth (31% per year) is above the savings rate (3.1%).

Earnings vs Market: ABBV's earnings (31% per year) are forecast to grow faster than the US market (15.5% per year).

High Growth Earnings: ABBV's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ABBV's revenue (7.1% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: ABBV's revenue (7.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ABBV's Return on Equity is forecast to be very high in 3 years time (303.2%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/24 16:30
End of Day Share Price	2025/10/24 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AbbVie Inc. is covered by 50 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Luisa Hector	Berenberg
Evan Seigerman	BMO Capital Markets Equity Research

AbbVie Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 20%, revenue upgraded

Recent updates

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 13%

Abbvie Announces Positive Topline Results from the Phase 3B/4 Head-To-Head Study

AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition

AbbVie Announces U.S. Food and Drug Administration Approves Updated Indication Statement for RINVOQ®? (upadacitinib) for the Treatment of Inflammatory Bowel Disease

Abbvie to Present New Data At Esmo 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

Upcoming dividend of US$1.64 per share

AbbVie Announces Positive Topline Results from Phase 2 Elite Trial Evaluating OnabotulinumtoxinA (BotoX®?) for the Treatment of Upper Limb Essential Tremor

AbbVie Inc. to Report Q3, 2025 Results on Oct 31, 2025

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab Sunirine (PVEK) - an Investigational Antibody-Drug Conjugate to Treat Rare Cancer with Limited Treatment Options

AbbVie Announces UK Pricing Strategy for ELAHERE®? (Mirvetuximab Soravtansine-gynx)

AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

AbbVie's VRAYLAR®? (Cariprazine) Now Publicly Reimbursed in Alberta

Second quarter dividend of US$1.64 announced

Abbvie Inc. Declares Quarterly Dividend, Payable on November 14, 2025

AbbVie Announces Updated Results from Phase 2 EPCORE®? NHL-6 Study Evaluating the Potential for Outpatient Monitoring of Epcoritamab in Patients with Relapsed/Refractory (R) Diffuse Large B-Cell Lymphoma (DLBCL)

Abbvie Announces Positive Topline Results from Second Phase 3 Up-Aa Trial Evaluating Upadacitinib (Rinvoq®?) for Alopecia Areata

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Capstan Therapeutics, Inc.

Executive VP & COO exercised options and sold US$6.1m worth of stock

Consensus EPS estimates fall by 20%, revenue upgraded

Insider recently sold US$2.6m worth of stock

New minor risk - Negative shareholders equity

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

AbbVie Reportedly in Talks to Acquire Gilgamesh in $1 Billion Deal

Abbvie Announces Positive Topline Results from Phase 3 Up-Aa Trial Evaluating Upadacitinib for Alopecia Areata

Abbvie Submits for U.S. FDA Approval of Combination Treatment of VENCLEXTA and Acalabrutinib for Previously Untreated Patients with Chronic Lymphocytic Leukemia

AbbVie Announces Availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada

Upcoming dividend of US$1.64 per share

AbbVie Inc. to Report Q2, 2025 Results on Jul 31, 2025

First quarter dividend of US$1.64 announced

AbbVie Inc Declares Quarterly Cash Dividend, Payable August 15, 2025

Genentech and AbbVie Provide Update on Phase III Verona Study

U.S. FDA Approves Expanded Indication for Abbvie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

Abbvie Features New Data Across Difficult-To-Treat Solid Tumors and Blood Cancers At Asco 2025

The Gross Law Firm Files Lawsuit Against Cerevel Therapeutics Holdings, Inc

AbbVie's (NYSE:ABBV) Soft Earnings Are Actually Better Than They Appear

Abbvie Announces U.S. FDA Approves Emrelis for Adults with Previously Treated Advanced Non-Small Cell Lung Cancer (Nsclc) with High C-Met Protein Overexpression

AbbVie Inc. Announces U.S. Food and Drug Administration Approval for Giant Cell Arteritis

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

AbbVie Q1 Earnings Review: Typically Strong Performance, Aesthetics Aside

AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines

AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)

AbbVie Inc. Announces European Commission Approval of RINVOQ (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis

Upcoming dividend of US$1.64 per share

Executive VP & Chief Commercial Officer recently sold US$7.0m worth of stock

Executive VP & Chief Commercial Officer notifies of intention to sell stock

AbbVie Inc. to Report Q1, 2025 Results on Apr 25, 2025

AbbVie Vs. Sanofi: Which Is The Better Investment Right Now

AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025

Executive VP & CFO recently sold US$3.7m worth of stock

Executive VP & CFO notifies of intention to sell stock

AbbVie Announces Final Analysis of the Confirmatory Phase 3 MIRASOL Trial Evaluating the Efficacy and Safety of ELAHERE®?

AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk

AbbVie Inc., Annual General Meeting, May 09, 2025

Executive Chairman recently sold US$20m worth of stock

AbbVie Announces SKYRIZI (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

Executive Chairman notifies of intention to sell stock

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®?) for the Treatment of Adults with Giant Cell Arteritis

Investors Don't See Light At End Of AbbVie Inc.'s (NYSE:ABBV) Tunnel

Why AbbVie Remains A Strong Buy For Long-Term Investors

Fourth quarter dividend of US$1.64 announced

AbbVie Inc. Announces Board Changes, Effective July 1, 2025

AbbVie: An Undervalued Dividend Aristocrat

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on May 15, 2025

Abbvie Announces the U.S. Food and Drug Administration Approves Emblaveo™

Full year 2024 earnings: EPS misses analyst expectations

AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Nimble Therapeutics, Inc.

Abbvie and Regenxbio Inc. Announce Updates on the Abbv-Rgx-314 Clinical Program

AbbVie's Stock Is Unfairly Cheap

Upcoming dividend of US$1.64 per share

AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year